Envestnet Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-9,867
| Closed | -$213K | – | 4711 |
|
|
2025
Q4 | $213K | Sell |
9,867
-3,684
| -27% | -$71.5K | ﹤0.01% | 4236 |
|
|
2025
Q3 | $207K | Sell |
13,551
-2,767
| -17% | -$36K | ﹤0.01% | 4303 |
|
|
2025
Q2 | $144K | Sell |
16,318
-12,358
| -43% | -$109K | ﹤0.01% | 4296 |
|
|
2025
Q1 | $225K | Buy |
28,676
+851
| +3% | +$7.13K | ﹤0.01% | 4088 |
|
|
2024
Q4 | $292K | Sell |
27,825
-32,618
| -54% | -$396K | ﹤0.01% | 3905 |
|
|
2024
Q3 | $793K | Sell |
60,443
-2,708
| -4% | -$41.3K | ﹤0.01% | 3265 |
|
|
2024
Q2 | $888K | Buy |
63,151
+47,822
| +312% | +$779K | ﹤0.01% | 3106 |
|
|
2024
Q1 | $259K | Buy |
+15,329
| New | +$228K | ﹤0.01% | 3804 |
|
|
2023
Q3 | – | Sell |
-14,214
| Closed | -$234K | – | 4015 |
|
|
2023
Q2 | $234K | Sell |
14,214
-19,842
| -58% | -$258K | ﹤0.01% | 3619 |
|
|
2023
Q1 | $11.2K | Buy |
+34,056
| New | +$280K | ﹤0.01% | 3945 |
|
|
2022
Q4 | – | Sell |
-13,619
| Closed | -$68K | – | 3951 |
|
|
2022
Q3 | $68K | Sell |
13,619
-26
| -0.2% | -$143 | ﹤0.01% | 3786 |
|
|
2022
Q2 | $33K | Buy |
13,645
+202
| +2% | +$829 | ﹤0.01% | 3853 |
|
|
2022
Q1 | $92K | Sell |
13,443
-6,065
| -31% | -$41.7K | ﹤0.01% | 3813 |
|
|
2021
Q4 | $158K | Buy |
19,508
+6,169
| +46% | +$56.4K | ﹤0.01% | 3699 |
|
|
2021
Q3 | $131K | Buy |
13,339
+23
| +0.2% | +$181 | ﹤0.01% | 3561 |
|
|
2021
Q2 | $90K | Buy |
+13,316
| New | +$106K | ﹤0.01% | 3573 |
|
|
2020
Q4 | – | Sell |
-11,543
| Closed | -$58K | – | 3272 |
|
|
2020
Q3 | $58K | Buy |
11,543
+688
| +6% | +$5.01K | ﹤0.01% | 3053 |
|
|
2020
Q2 | $88K | Buy |
+10,855
| New | +$95.7K | ﹤0.01% | 2994 |
|
|
2019
Q4 | – | Sell |
-14,951
| Closed | -$62K | – | 3081 |
|
|
2019
Q3 | $62K | Sell |
14,951
-207
| -1% | -$518 | ﹤0.01% | 2980 |
|
|
2019
Q2 | $44K | Buy |
15,158
+4,259
| +39% | +$7.32K | ﹤0.01% | 2997 |
|
|
2019
Q1 | $16K | Buy |
10,899
+262
| +2% | +$593 | ﹤0.01% | 2947 |
|
|
2018
Q4 | $27K | Buy |
+10,637
| New | +$36.2K | ﹤0.01% | 2824 |
|
|
2018
Q3 | – | Sell |
-1,096
| Closed | -$7K | – | 1339 |
|
|
2018
Q2 | $7K | Hold |
1,096
| – | – | ﹤0.01% | 2598 |
|
|
2018
Q1 | $8K | Sell |
1,096
-427
| -28% | -$3.76K | ﹤0.01% | 2528 |
|
|
2017
Q4 | $12K | Buy |
1,523
+1,010
| +197% | +$9.47K | ﹤0.01% | 2593 |
|
|
2017
Q3 | $5K | Sell |
513
-26
| -5% | -$248 | ﹤0.01% | 2702 |
|
|
2017
Q2 | $6K | Sell |
539
-6
| -1% | -$60 | ﹤0.01% | 2792 |
|
|
2017
Q1 | $5K | Buy |
+545
| New | +$5.45K | ﹤0.01% | 2891 |
|
|
2016
Q2 | – | Sell |
-1,023
| Closed | -$11K | – | 3068 |
|
|
2016
Q1 | $11K | Sell |
1,023
-84
| -8% | -$834 | ﹤0.01% | 3029 |
|
|
2015
Q4 | $14K | Sell |
1,107
-361
| -25% | -$5.63K | ﹤0.01% | 2924 |
|
|
2015
Q3 | $24K | Buy |
+1,468
| New | +$32.3K | ﹤0.01% | 2878 |
|
Other funds holding AVDL
Envestnet Asset Management's AVDL Position: Q1 2026 in Review
Envestnet Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 9,867 shares — an estimated $213K sold.
Envestnet Asset Management first reported a position in AVDL in Q3 2015 and held it in 31 quarters. The position peaked at $888K in Q2 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Envestnet Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Envestnet Asset Management sold 9,867 Avadel Pharmaceuticals shares in Q1 2026, an estimated $213K.
- Envestnet Asset Management first reported a position in Avadel Pharmaceuticals in Q3 2015 and held it in 31 quarters.
- Envestnet Asset Management's Avadel Pharmaceuticals position peaked at $888K in Q2 2024.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Envestnet Asset Management's 13F filing for Q1 2026, filed 4 May 2026.